Skip to Content

AstraZeneca PLC ADR

AZN: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$16.00QljcQqspgtmdy

AstraZeneca Earnings: Strong Growth, but Approaching Generics Weigh on Long-Term Outlook

AstraZeneca reported strong first-quarter results that fell largely in line with our expectations, so we are holding firm to our fair value estimate.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of AZN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center